Table 7 Progression-free survival analysis results.

From: Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer

Follow-up period

Control group survivors (%)

Experimental group survivors (%)

Chi-squared

P-value

Significance

1-year

34 (82.93%)

38 (92.68%)

1.025

0.311

No

2-year

19 (46.34%)

22 (53.66%)

0.195

0.659

No

3-year

3 (7.32%)

10 (24.39%)

3.291

0.07

No

Back to article page